ArticleGenome research2011
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.
Article in Genome research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 5 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- Dampened Regulatory Circuitry of TEAD1/ITGA1/ITGA2 Promotes TGFβ1 Signaling to Orchestrate Prostate Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Pooled it
- Advances in sequencing and omics studies in prostate cancer: unveiling molecular pathogenesis and clinical applications.Frontiers in oncology · 2024Pooled it
- Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancer.Aging · 2018Pooled it
- Global DNA hypomethylation in prostate cancer development and progression: a systematic review.Prostate cancer and prostatic diseases · 2015Pooled it
- Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.PloS one · 2014Trial
- Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer.The American journal of pathology · 2013Trial
- NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation.bioRxiv : the preprint server for biology · 2026Article
- Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.British journal of cancer · 2026Article
- Liquid Biopsy in Advanced Prostate Cancer.Cancers · 2026Review
- CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancer.Genes & genomics · 2025Article
- Alteration of chromatin states perturb the transcription regulation of gene during hydronephrosis.Frontiers in genetics · 2025Article
- Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.Nature cell biology · 2024Article
- A novel family of beta mixture models for the differential analysis of DNA methylation data: An application to prostate cancer.PloS one · 2024Article
- DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia.Prostate international · 2023Article
- Article
- Recent advances in understanding DNA methylation of prostate cancer.Frontiers in oncology · 2023Review
- Integrative multi-omic analysis identifies genetically influenced DNA methylation biomarkers for breast and prostate cancers.Communications biology · 2022Article
- Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.Nutrients · 2022Review
- Targeting the methionine addiction of cancer.American journal of cancer research · 2022Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 3 countries.
Funding
Abstract
Beginning with precursor lesions, aberrant DNA methylation marks the entire spectrum of prostate cancer progression. We mapped the global DNA methylation patterns in select prostate tissues and cell lines using MethylPlex-next-generation sequencing (M-NGS). Hidden Markov model-based next-generation sequence analysis identified ∼68,000 methylated regions per sample. While global CpG island (CGI) methylation was not differential between benign adjacent and cancer samples, overall promoter CGI methylation significantly increased from ~12.6% in benign samples to 19.3% and 21.8% in localized and metastatic cancer tissues, respectively (P-value < 2 × 10(-16)). We found distinct patterns of promoter methylation around transcription start sites, where methylation occurred not only on the CGIs, but also on flanking regions and CGI sparse promoters. Among the 6691 methylated promoters in prostate tissues, 2481 differentially methylated regions (DMRs) are cancer-specific, including numerous novel DMRs. A novel cancer-specific DMR in the WFDC2 promoter showed frequent methylation in cancer (17/22 tissues, 6/6 cell lines), but not in the benign tissues (0/10) and normal PrEC cells. Integration of LNCaP DNA methylation and H3K4me3 data suggested an epigenetic mechanism for alternate transcription start site utilization, and these modifications segregated into distinct regions when present on the same promoter. Finally, we observed differences in repeat element methylation, particularly LINE-1, between ERG gene fusion-positive and -negative cancers, and we confirmed this observation using pyrosequencing on a tissue panel. This comprehensive methylome map will further our understanding of epigenetic regulation in prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.